Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer
Michael Engsig, Chief Executive Officer of Nykode Therapeutics, stated: “The decision to focus on locally advanced cervical cancer and recurrent metastatic head and neck, and discontinue the C-04 trial in 2L cervical cancer, is part of our strategic repositioning to concentrate resources on the most commercially promising areas where we create significant benefits for patients in need, while generating value for shareholders. We remain highly enthusiastic about the broad potential of VB10.16 to make a meaningful difference in the lives of patients with HPV-driven cancers. While we regret the impact of excluding 2L cervical cancer from our immediate pipeline, we are eager to advance VB10.16 where we see the highest likelihood of clinical efficacy and the greatest market potential.
Share:
More News
Lamine Mbow, Global Head of Discovery Research, Boehringer Ingelheim, said: “We are building a broad pipeline of ADCs addressing novel tumor target space to develop next-generation cancer treatments. By combining our deep expertise in cancer treatment development with Synaffix’s clinical-stage platform technology, we aim to accelerate the delivery of first-in-class
“The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase 3 CREST results are potentially practice-changing, representing the first advance in therapy for BCG-naïve, high-risk, non-muscle invasive cancer in over 30 years,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “These
“Receiving FDA IND clearance is an important milestone in the advancement of TYRA-300 and for patients with NMIBC who urgently need better tolerated therapeutic options,” commented Doug Warner, Chief Medical Officer of TYRA. “We look forward to leveraging Erik’s impressive background to guide our development plans in NMIBC. We expect
“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance
